Cellectis Stock Price, News & Analysis

Cellectis (NASDAQ:CLLS), a clinical-stage biotechnology company focused on gene-editing therapies, held its shareholders general meeting on June 26, 2025. With approximately 57% of voting rights exercised, shareholders approved 25 out of 26 resolutions.

The meeting resulted in significant board changes: Mr. André Muller, current CEO of Idorsia Pharmaceuticals, was appointed as a new board member, while Mr. Pierre Bastid resigned and Mr. Axel-Sven Malkomes' term expired. Muller brings extensive experience from his roles at Idorsia, Actelion Pharmaceuticals, and Pierre Fabre SA.

Cellectis (CLLS) has released its monthly share capital and voting rights report as of May 31, 2025. The company reported a total of 100,325,229 shares in its capital structure, with 89,110,384 total voting rights. This disclosure is made in accordance with Article 223-16 of the General Regulation of the French financial markets authority. The company maintains its listing on Euronext Growth under the ISIN code FR0010425595.

Cellectis (NASDAQ: CLLS), a clinical-stage biotechnology company focused on gene-editing and cell and gene therapies, has announced its upcoming annual shareholders general meeting. The meeting is scheduled for June 26, 2025, at 2:30 p.m. CET and will be held at the Biopark auditorium in Paris, France. Shareholders can access detailed information about the meeting agenda and participation modalities through the company's website.

Cellectis (NASDAQ: CLLS) reported Q1 2025 financial results and provided pipeline updates. The company reported a cash position of $246 million as of March 31, 2025, providing runway into H2 2027. Key pipeline developments include expected Phase 1 data for lasme-cel (UCART22) in Q3 2025 and eti-cel (UCART20x22) readout in late 2025. The company's partnership with AstraZeneca continues with ongoing R&D activities in three programs. Financial highlights include: - Revenue increased to $12.0 million vs $6.5 million in Q1 2024 - R&D expenses decreased to $21.9 million from $22.3 million - Net loss of $18.1 million ($0.18 per share) compared to net income of $5.6 million in Q1 2024 - Cash burn of $18 million during Q1 2025

Cellectis (CLLS) has released its monthly share capital and voting rights report as of April 30, 2025. The company reported a total of 100,290,220 shares in its capital structure, with 89,075,490 total voting rights. This disclosure is made in accordance with Article 223-16 of the General Regulation of the French financial markets authority, as the company is listed on Euronext Growth.

Cellectis (NASDAQ: CLLS), a clinical-stage biotechnology company focused on gene-editing and cell therapy development, has announced it will release its first quarter 2025 financial results on Monday, May 12, 2025, after the US market closes. The financial results will be accessible through a press release in the Investors section of the company's website. Unlike typical earnings releases, Cellectis will not host a conference call to discuss the results, though their investor relations team will remain available to address questions via email at investors@cellectis.com.

Cellectis unveiled groundbreaking research data on gene-editing technologies at the upcoming Society of Gene and Cell Therapy annual meeting in New Orleans (May 13-17, 2025). The company presented two significant innovations:

1. TALEN-Mediated Non-viral Transgene Insertion:

• Successfully combined TALEN gene editing with non-viral delivery methods
• Demonstrated high efficiency in T-cells and blood stem cells
• Showed better cell fitness and stability compared to traditional viral methods
• Addresses challenges of viral methods like manufacturing limits and toxicity risks

2. TALE Base Editors (TALEB) Development:

• Created new method for precise C-to-T DNA conversion
• Achieved efficient editing without DNA strand damage
• Showed no detectable off-target editing in primary cells
• Developed system to assess editing efficiency across different sequences

These breakthroughs could advance treatments for cancer, autoimmune diseases, and genetic disorders. The complete research data will be available on Cellectis' website when the event begins.

Cellectis (CLLS) has released its monthly share capital and voting rights report as of March 31, 2025. The company reported a total of 100,290,078 shares in its capital structure, with 89,046,759 total voting rights. This disclosure complies with Article 223-16 of the General Regulation of the French financial markets authority for companies listed on Euronext Growth.

Cellectis (CLLS) reported its Q4 and full year 2024 financial results, highlighting significant progress in its clinical programs and strategic partnerships. The company maintains a strong cash position of $264 million, providing runway into mid-2027.

Key pipeline updates include:

• UCART22 Phase 1 data and development strategy expected in Q3 2025, with FDA granting Orphan Drug and Rare Pediatric Disease Designations
• UCART20x22 Phase 1 study in NHL ongoing with readout expected late 2025
• Three active programs in collaboration with AstraZeneca

Notable corporate developments include AstraZeneca's $140 million additional equity investment and the completion of European Investment Bank financing drawdown of €40 million. The company has deprioritized UCART123 development to focus on BALLI-01 and NATHALI-01 studies.